The plan of optimizing Helicobacter pylori eradicatio

Phase 1

Recruiting

• Conditions: Helicobacter pylori infection

• Registration Number: ITMCTR1900002441
• Lead Sponsor: Hubei Provincial Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

(1) All subjects met the diagnostic criteria for Hp gastritis: 13C or 14C breath test showed that Hp was positive, with symptoms of abdominal distension, noise, belching and burning. Chronic superficial gastritis with or without chronic atrophic gastritis was diagnosed by gastroscopy, regardless of whether Hp had been eradicated in the past or not, and antibiotics, bismuth or antimicrobial Chinese medicine were discontinued at least 4 weeks before consultation. PPI or gastric mucosal protective agents must be discontinued for at least 2 weeks.
(2) Only group D conformed to the following syndromes
Syndrome of damp-heat in spleen and stomach:
Main symptoms: fullness or pain of abdomen; body distress; sticky stool or runny stool;
Secondary syndromes: less food, less stupor; bad breath; bitter mouth; mental sleepiness;
Tongue vein: red tongue, yellow greasy fur, pulse number or slippery.
(3) The age ranges from 18 to 65 years with no gender limitation.
(4) Informed consent and voluntary participation.

Exclusion Criteria

One of the following situations can not be included in this study:
(1) Subjects diagnosed by examination as peptic ulcer, gastric cancer, reflux esophagitis, irritable bowel syndrome and other diseases affecting symptoms and manifestations.
(2) Signs of infection were obvious, with white blood cells > 10.0*10^9.
(3) Antibiotics, bismuth or traditional Chinese medicine with antimicrobial activity were used within 4 weeks, PPI or other gastric drugs were used within 2 weeks.
(4) Pregnant and lactating women.
(5) Severe primary heart, liver, lung, kidney, blood diseases or serious diseases affecting their survival, such as malignant tumors.
(6) Those who cannot give full informed consent due to intellectual or behavioral disorders.
(7) Suspected or true history of alcohol and drug abuse.
(8) Subjects whose work environment has changed greatly or whose compliance is poor have lost their follow-up visits or failed to awaken follow-up as planned.
(9) allergic constitution or drug allergy to test group and control group.

Study & Design

• Study Type: Observational study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication rate of Helicobacter pylori;